Updates are available Correction dated 2022-11-03
Click to view Correction: https://doi.org/10.1007/s11912-022-01336-7
-
Authors
Balducci, Lodovico
Falandry, Claire
List, Alan
- License Information
-
More Information
Article History
Accepted: 28 July 2022
First Online: 20 August 2022
Change Date: 3 November 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s11912-022-01336-7
Declarations
:
: Lodovico Balducci is consultant for Aileron therapeutic.Claire Falandry has received research funding from Chugai Pharmaceutical Co., Ltd., Pfizer, Astellas Pharma, and Laboratoires Pierre Fabre; has received speaker's honoraria from Leo Pharma, Pfizer, MSD Oncology, Janssen Oncology, Teva Pharmaceuticals, AstraZeneca, Baxter International, Eisai, Novartis, Chugai Pharmaceutical Co., Ltd., and Astellas Pharma; has received travel support from Janssen Oncology, GSK Oncology, Laboratoires Pierre Fabre, AstraZeneca, and Leo Pharma.Alan List has received compensation for service as a consultant from Aileron Therapeutics, and also has stock options in Aileron Therapeutics.
: This article does not contain any studies of human or animal subjects performed by any of the authors.
